Celonis, the global leader in Process Mining and Process Intelligence, today announced the appointment of Kaushik Mitra as Vice President and Head of India Go-to-Market (GTM). Mitra will lead Celonis' ...

I also consulted the Merck Veterinary Manual for general information ... to ensure safe and effective use. You can purchase logo and accolade licensing to this story here. Disclosure: Written ...

Our recommendations adhere to the standards set by the Association of American Feed Control Officials (AAFCO) and the Global Nutrition Guidelines from the World Small Animal Veterinary Association ...

In a decision filed March 28, Hon. Steven C. Seeger granted The Lansing Journal’s motion to dismiss the lawsuit filed by Lan-Oak Park District ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs (shareholders) alleged that they bought MRK stock at artificially inflated ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said ... down 7:10 AM UTC Healthcare & Pharmaceuticalscategory Small-town Ireland nervous as Trump seeks to lure pharma investment ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and non-small cell lung cancer (NSCLC).

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.